



## p53 EXPRESSION IN EPITHELIAL CELL PROLIFERATION AMONG VARIANTS OF AMELOBLASTOMAS

Shashi Ranjan<sup>1</sup>, Rashmi Issar<sup>\*2</sup>, Deepa Hugar<sup>3</sup> and Priyankar Singh<sup>4</sup>

<sup>1</sup>Department of Oral & Maxillofacial Pathology, Dr.B.R. Ambedkar Institute of Dental Sciences & Hospital, Patna, Bihar

<sup>2</sup>Department of Conservative Dentistry & Endodontics, Patna Dental College & Hospital, Patna, Bihar

<sup>3</sup>Dept of Oral and Maxillofacial Pathology, Albadar Dental College and Hospital, Gulbarga, Karnataka, India

<sup>4</sup>Dept of Dentistry, JLNMCH, Bhagalpur, Bihar

### ARTICLE INFO

#### Article History:

Received 15<sup>th</sup> July, 2019

Received in revised form 7<sup>th</sup>

August, 2019

Accepted 13<sup>th</sup> September, 2019

Published online 28<sup>th</sup> October, 2019

#### Key words:

cyst, immunohistochemistry, mean labelling index, odontogenic tumors, p53

### ABSTRACT

**Introduction:** Ameloblastoma has a diverse clinicopathological appearance. Several treatment modalities have been implicated based on such morphology. In this study we are evaluating tumor marker p53 in various histological and clinical subtypes of ameloblastomas.

**Background:** The primary aim of the study is to know the behaviour of various clinicopathological variants of ameloblastomas on the basis of p53 expression in its epithelial cell proliferation.

**Methods:** Most common variants of ameloblastomas (n=20) consisting six follicular ameloblastomas (FA), six plexiform ameloblastomas (PA), two granular cell ameloblastomas (GCA) and six unicystic ameloblastomas (UA) with luminal proliferation were selected and examined morphologically and immunohistochemically for changes in proliferative activity using p53 marker.

**Results:** p53 labelling index was significantly higher in FA, PA, UA than GCA. But mean labelling index of p53 expression was insignificant among FA, PA, and UA. Among various histopathological variants highest p53 mean labeling index was observed in follicular ameloblastoma (70.4%) followed by unicystic ameloblastoma (65%), plexiform ameloblastoma (64.6%) and was minimal in granular cell ameloblastoma (6.2%).

The Pearson correlation (which is significant at the 0.01 level) for p53 expression among variants of ameloblastomas was insignificant (.977)

**Conclusion:** The pattern of expression of p53 varies among variants of ameloblastomas so it clearly indicates that it is not fruitful to correlate and compare p53 marker in ameloblastomas despite individually p53 marker is useful to assess the neoplastic behavior and recurrence of ameloblastomas. Also it can be concluded that histopathological variants have no or little role in assessing the behavior and prognosis and all ameloblastomas should be assessed clinically for treatment modalities.

Copyright©2019 Shashi Ranjan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### INTRODUCTION

Ameloblastoma is the most frequently encountered benign epithelial odontogenic tumor(1,2) and is characterized by a locally invasive behaviour with a high risk of recurrence rate despite radical therapy.(3,4) Histopathologically, ameloblastomas show different variants including follicular, plexiform, acanthomatous, granular cell, clear cell, desmoplastic, basal cell, mucinous, hemangiomatous, papilliferous keratoameloblastoma and clinical variants like peripheral, metastasizing and unicystic ameloblastomas with variable growth pattern including luminal, intraluminal and mural proliferation (1,5).

\*Corresponding author: Rashmi Issar

Department of Conservative Dentistry & Endodontics,  
Patna Dental College & Hospital, Patna, Bihar

It has been reported that the aggressiveness of ameloblastomas may be related to the histological subtype(3), infact in a review of the literature for plexiform, follicular, acanthomatous and unicystic ameloblastoma recurrence rates, respectively, of 16.7%, 29.5%, 4.5%, and 13.7%.(4) Several studies have detected genetic and cytogenetic alterations in these epithelial odontogenic tumors; however the detailed mechanism of oncogenesis, cytodifferentiation remain unknown(6,7,8,9).

p53 is a mutated product of tumor suppressor gene p53. It has a short half life in normal cells and cannot be detected immunocytochemically, but when it mutates, the p53 protein product is more stable and can be detected immunocytochemically. It has been widely used for diagnosis of malignant tumors.(10-12)

As we know that irreversible increased cellular proliferation is a phenomenon of tumor, so in our study we are using p53 marker to assess mutated p53 epithelial cell expression among histological variants of ameloblastomas including follicular, plexiform, granular cell ameloblastomas and unicystic ameloblastoma with luminal proliferation.

**MATERIALS AND METHODS**

The study material comprised of archival formalin fixed paraffin embedded specimens of patients from private oral pathology laboratory as 20 cases of ameloblastomas. The cases were selected on the basis of most commonly encountered clinicopathological variants of ameloblastomas and included 6 cases of follicular ameloblastoma, 6 cases of plexiform ameloblastoma, 2 cases of granular cell ameloblastoma and 6 cases of unicystic ameloblastoma with luminal proliferation.

All selected cases had been routinely fixed in 10% neutral formalin (24-48 h), dehydrated in graded alcohols, cleared in xylene and embedded in paraffin. Using haematoxylin and eosin-stained sections, all the slides were reviewed, the quality of the material was checked and the slides for the quantitative evaluation of the material were selected. In each case the slides selected showed the peripheral and the central zone of the tumour. Each individual tissue block was cut for one individual slides. 1 Control slide was also made for each group of cases. Standard immunohistochemistry staining protocol was performed (9) using primary antibody monoclonal mouse anti-human p53 (1:100 prediluted) (1:100 prediluted) and super sensitive poly horse radish peroxidase (HRP) secondary antibody kit (Biogenex India private limited). Slides were checked for positive staining as crisp, brown nuclear staining for p53 in respective sections. Positive controls were obtained from colonic adenocarcinoma for p53. Negative controls were included by performing duplicate assays, in which the primary antibody was replaced with phosphate buffer saline.

**Evaluation of p53 Staining**

Representative fields were selected in each case as randomly or without bias as possible. These areas included only labelled cystic or tumor epithelial areas and excluded areas of necrosis, inflammation, and stromal cells. Representative fields were selected in each case of solid and multicystic ameloblastomas and along the cyst lining of unicystic variant. All cell counts were performed with a Olympus Ch20i microscope fitted with an eyepiece graticule, x10 oculars, a x40 objective, and a counting grid containing 400 blocks in conjunction with a hematology laboratory differential cell counter (Olympus India limited). The cases were scored by counting the positive cells per minimum of 500 tumor cells per specimen. The percentage labelling index (number of positive tumor cells/total number of tumor cells expressed as a percentage) was calculated per case. To determine intraobserver and interobserver reliability, the same examiner counted the cells in each case twice at one hour interval while a second examiner counted the cells independently in a sample of the cases using the same positions of the grid.

**Statistical analysis**

Descriptive statistical analysis was performed for each group of lesions by statistical software program SPSS (version 16.0). The mean labeling indices were compared by using an analysis of variance test (ANOVA) for p53 marker. Kruskal-Wallis Test were then performed to determine statistically significant


differences in p53 expression overall. Probability levels of < 0.05 were regarded as being statistically significant. To satisfy the statistical assumptions of the tests, all data were square root transformed before analysis.

**RESULTS**

Positive cases were selected on basis of positive staining by p53 marker in same cases.(Graph 1) There was no significant difference found among follicular, plexiform and unicystic ameloblastomas for mean labelling index of p53 marker but these variants shows significantly higher mean labelling index than granular cell ameloblastomas for p53 marker. (p=.041)(Graph-2)


The pearson correlation (which is significant at the 0.01 level) p53 expression among variants of ameloblastomas was insignificant.(.977)

Nuclear p53 reactivity was exhibited by ameloblastomas, mostly in basal and parabasal odontogenic epithelial cells in many areas of different variants of ameloblastomas. Among various histopathological variants highest p53 mean labelling index was observed for follicular ameloblastoma followed by unicystic and plexiform ameloblastoma and was minimal in granular cell ameloblastoma. (Figure1-4)



**Graph 1** Immunopositive Samples of Ameloblastomas

(FA-Follicular Ameloblastoma, PA-Plexiform Ameloblastoma, UA- Unicystic Ameloblastoma, GCA- Granular Cell Ameloblastoma, n=Number Of Cases)



**Graph 2** Mean Labeling Index For Ki-67 and p53 In Ameloblastomas

(FA-Follicular Ameloblastoma, PA-Plexiform Ameloblastoma, UA- Unicystic Ameloblastoma, GCA- Granular Cell Ameloblastoma)




Figure Legends-1(A-B) Follicular ameloblastoma(FA), 1A-H&E section of follicular ameloblastoma (10x), 1B Positive p53 expression in peripheral & central cells of follicular ameloblastoma(40x), 2(A-B) Plexiform ameloblastoma(PA), 2A-H&E section of plexiform ameloblastoma (10x), 2B- Positive p53 expression in peripheral & central cells of plexiform ameloblastoma(40x), 3 (A-B) Unicystic Ameloblastoma, 3A-H&E section of unicystic ameloblastoma (10x), 3B- Positive p53 expression in basal & suprabasal cells of unicystic ameloblastoma(10x), 4 (A-D) Granular cell ameloblastoma(GCA), 4A-H&E section of granular cell ameloblastoma (10x), 4D-Sparse positive p53 expression in basal & central cells of granular cell ameloblastoma(40x)

## DISCUSSION

Many investigation of tumor cell proliferative activity and role of p53 in tumorigenesis have been evaluated using Ki-67 and p53 in oral and other systemic tumors.(10-13) Kumamoto *et al* found no or little p53 expression in tooth germ tissue whereas nuclear positivity was seen in benign and malignant ameloblastomas and suggested that p53 expression is associated with oncogenesis of odontogenic epithelium. (10) However many studies on p53 has shown that it is not consistently expressed in odontogenic lesions and whatever expression occur is due to over expression and not due to mutation (14).

In this study, assessment of cellular proliferation markers was shown to be accurate, reliable and reproducible and produced excellent comparable results. The use of labelling indices has, however, proven to be extremely tedious for routine application in the assessment of cellular proliferation.

Keeping the concept of tumor in mind the most common property is excessive proliferation of tumor cell thought to be arising from mutation of p53 tumor suppressor gene or its product, we carried out this study with selection of p53 marker to put the concept of tumor proliferation due to mutated p53 gene in tumorigenesis by comparing the expression of p53 in epithelial component of these groups.(13)

Variable expression of p53 noted among histopathological variants of ameloblastomas. p53 expression was higher in follicular type than plexiform and unicystic type suggesting that tissue structuring of ameloblastomas might be affected by p53 expression.(10) High proliferative activity seen in all the variants except granular cell ameloblastoma. Granular cell ameloblastoma showed minimal p53 expression and it has been shown that granular cells shows increased apoptotic cell death as compared with other neoplastic cells. So apoptosis of these cells was not induced by a p53-dependent pathway.(10,15,16) Granular cell variant minimal cellular proliferation and p53 expression can also be explained on the basis of loss or inactivation of signaling pathways related to cell proliferation and differentiation in the granular cells, suggesting that these cells are functionally inactive and their synthesis and secretion activities have become irregular (17).

Unicystic ameloblastoma showed statistically significantly higher p53 labelling indices almost similar to solid variants. It was similar to results of Meer *et al*(9) and this variation can be attributed to difference in methodology, especially the counting protocol, used. Unfortunately it is very difficult to compare these parameters because published reports frequently fail to provide sufficient detail or explanation. Another possible reason might be the difference in the morphology of the tumors, with the solid lesions providing large follicles or plexiform sheets for analysis, whereas only a thin lining is available in the unicystic cases. This may have resulted in the inclusion of greater numbers of basal and parabasal cells in the unicystic group, thus resulting in higher mean labeling indices. This is unlikely as cells in the entire thickness of the epithelial linings of the unicystic lesions were included in the count (9). Inclusion of granular cell variant has resulted in decreased overall expression of p53 marker.(17)

p53 marker was observed predominantly in peripheral cells of tumor island and cystic lining. This could explain the locally infiltrating growth of ameloblastomas and its aggressive behaviour. Difference in morphology of ameloblastomas facilitates more difficulty in surgical accessibility of conventional ameloblastomas than unicystic ameloblastomas. So it can explain recurrence and worse prognosis in conventional ameloblastomas than unicystic ameloblastomas. (9)

It has been proposed that odontogenic tumor may follow p53 independent pathway for tumorigenesis, so doesn't express p53.(15,16) Recent advancement has shown various molecular markers in tumor growth and its behaviour including vascular endothelial growth factors (VEGF) which has been found to be minimally expressed in acanthomatous and granular cell ameloblastoma than other histological variants. Also mutation in PTEN (phosphatase and tensin homolog deleted on chromosome 10) has been shown to occur in ameloblastomas and in carcinogenesis, loss of PTEN allows for overactivity of the phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathway inducing an upregulation of mammalian target of rapamycin (mTOR) and its downstream effector ribosomal subunit-6 kinase (S6K); allowing for uncontrolled cell proliferation, apoptosis inhibition and cell cycle deregulation. Aberrant signalling in the PI3K/AKT/mTOR pathway may be the cause of aggressiveness of ameloblastomas.(8)

## CONCLUSION

So overall result clearly indicates the pattern of expression of p53 varies among variants of ameloblastomas so it is not fruitful to correlate and compare p53 marker in ameloblastomas despite individually p53 marker is useful to assess the neoplastic behaviour of ameloblastomas. p53 overexpression may be involved in pathogenesis of ameloblastomas and can be used to assess aggressive behaviour of various clinicopathological variants of ameloblastomas. Also anti p53 agent could be considered to reduce the size of large tumors and to treat unresectable tumors that are in close proximity to vital structures.

Our study clearly indicated that except granular cell ameloblastoma, other variants of ameloblastomas have high proliferative potential. Granular cell ameloblastoma shows minimal proliferation and can be explained on molecular and pathogenetic basis as initially we use term granular cell changes in ameloblastoma suggesting that these changes are initiating in central stellate reticulum like cells of either follicular or plexiform ameloblastoma and in course of time granular cell changes involves even peripheral ameloblastoid cells and presents as extensive granular cell changes in whole tumor mass and at this time term granular cell ameloblastoma should be applied. (14-16,18) So granular cell ameloblastoma can be considered as mature tumor showing minimal proliferation based on our results as well as previous molecular studies. So apart from proliferative potential, it is the ease with which a tumor can be removed will decide the tumor behaviour. So all ameloblastomas should be assessed clinically for treatment modalities.

However further study with large sample size of different clinicopathological variants and other relevant tumor marker analysis will be required to confirm these findings and to make a definite cause and effect relationship.

## References

1. Merva Soluk-Tekkesin, John M. Wright. The world health organization classification of odontogenic lesions: a summary of the changes of the 2017 (4<sup>th</sup>) edition. *Turkish Journal of Pathology*; 2018;34(1-16)
2. Funaoka K, Arisue M, Kobayashi I, Iizuka T, Kohgo T, Amemiya A, Totsuka Y. Immunohistochemical detection of proliferating cell nuclear antigen (PCNA) in 23 cases of ameloblastoma. *Oral Oncol, Eur J Cancer* 1996; 32B:328±332.
3. Kim J, In Yook J. Immunohistochemical study on proliferating cell nuclear expression in ameloblastomas. *Oral Oncol, Eur J Cancer* 1994; 30B:126±131.
4. Reichart PA, Philipsen HP, Sonner S. Ameloblastoma: biological profile of 3677 cases. *Oral Oncol, Eur J Cancer* 1995; 31B:86±99.
5. SB RAHMAN, SMA SADAT, IA HAIDER, M AHMED: Analysis of Histological Variants of Ameloblastomas of Jaws in Relation to their Clinical Presentations: *Journal of Bangladesh College of Physicians and Surgeons* Vol. 35, No. 2, April 2017.
6. A. Piattelli, M. Fioroni, A. Santinelli, C. Rubini. Expression of proliferating cell nuclear antigen in ameloblastomas and odontogenic cysts. *Oral Oncology* 34 (1998) 408-412.
7. Alma Florescu, Cristiana Simionescu, Raluca Ciurea, Allma Pitru: P53, Bcl-2 and Ki67 immunoexpression in follicular solid ameloblastomas; *Rom J Morphol Embryol* (2012), 53(1):105-109
8. Ravleen Nagi, Shashikant Sahu, N Rakesh; Molecular and genetic aspects in the etiopathogenesis of ameloblastoma: An update: *Journal of Oral and Maxillofacial Pathology*, Sep- Dec 2016 (Vol 20) Issue 3
9. Shabnum Meer, Jacqueline S. Galpin, Mario Altin, Hedley Coleman, Hasiena Ali. Proliferating cell nuclear antigen and Ki-67 immunoreactivity in ameloblastomas. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2003; 95:213-21.
10. Hiroyuki Kumamoto, Takashi Izutsu, Kousuke Ohki, Nobuhiro Takahashi, Kiyoshi Ooya. p53 gene status and expression of p53, MDM2, and p14 ARF proteins in ameloblastomas. *J Oral Pathol Med* (2004) 33: 292-9.
11. Slootweg PJ. p53 protein and Ki-67 reactivity in epithelial odontogenic lesions. An immunohistochemical study. *J Oral Pathol Med* (1995) 24: 393-397.
12. IJN Carvalhais, MCF de Aguiar, VC de Araujo, NS de Araujo, RS Gomez. p53 and MDM2 expression in odontogenic cysts and tumours. *Oral Diseases* (1999) 5, 218-222.
13. Amol Ramchandra Gadbail, Rahul Patil & Minal Chaudhary: Co-expression of Ki-67 and p53 protein in ameloblastoma and keratocystic odontogenic tumor; *Acta Odontologica Scandinavica*, 2012; 70: 529-535
14. Li TJ, Browne RM, Matthews JB. Quantification of PCNA+ cells within odontogenic jaw cyst epithelium. *J Oral Pathol Med* (1994) 23:184-189.
15. Kumamoto H. Detection of apoptosis-related factors and apoptotic cells in ameloblastomas: analysis by immunohistochemistry and an in situ DNA nick-end labelling method. *J Of Oral Pathol Med* 1997; 26: 419-25.
16. Kumamoto H, Kimi K, Ooya K. Immunohistochemical analysis of apoptosis related factors (Fas, Fas ligand, caspase-3 and single stranded DNA) in ameloblastomas. *J Of Oral Pathol Med* 2001; 30: 596-602.
17. Sathi Gul San Ara, Phuu Pwint Han, Ryo Tamamura, Hitoshi Nagatsuka, Hailong Hu, Naoki Katase, Noriyuki Nagai. Immunolocalization of cell signaling molecules in the granular cell ameloblastoma. *J of oral pathol med* (2007) 36; 609-14.
18. Neville BW, Damm DD, Allen CM, Bouquot JE. *Oral and maxillofacial pathology*. 3rd edition. Saunders; 2009. 706

### How to cite this article:

Shashi Ranjan et al (2019) 'p53 Expression in Epithelial Cell Proliferation among Variants of Ameloblastomas', *International Journal of Current Advanced Research*, 08(10), pp. 20236-20239.  
DOI: <http://dx.doi.org/10.24327/ijcar.2019.20239.3946>